Axcelis Technologies, Inc. (ACLS) Stake Maintained by Nationwide Fund Advisors

Nationwide Fund Advisors held its position in shares of Axcelis Technologies, Inc. (NASDAQ:ACLS) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,024 shares of the semiconductor company’s stock at the end of the 2nd quarter. Nationwide Fund Advisors owned 0.08% of Axcelis Technologies worth $503,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ACLS. Peregrine Capital Management LLC increased its position in shares of Axcelis Technologies by 405.6% during the 2nd quarter. Peregrine Capital Management LLC now owns 572,856 shares of the semiconductor company’s stock valued at $12,001,000 after purchasing an additional 459,560 shares during the last quarter. Bank of Montreal Can increased its position in shares of Axcelis Technologies by 106,193.5% during the 2nd quarter. Bank of Montreal Can now owns 329,510 shares of the semiconductor company’s stock valued at $6,902,000 after purchasing an additional 329,200 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Axcelis Technologies by 10.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,766,009 shares of the semiconductor company’s stock valued at $33,200,000 after purchasing an additional 163,016 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Axcelis Technologies by 247.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 161,665 shares of the semiconductor company’s stock valued at $3,386,000 after purchasing an additional 115,111 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Axcelis Technologies during the 2nd quarter valued at about $1,843,000. 74.68% of the stock is owned by hedge funds and other institutional investors.

Axcelis Technologies, Inc. (NASDAQ ACLS) opened at $35.20 on Friday. The company has a market cap of $997.60 million, a PE ratio of 28.27, a P/E/G ratio of 1.25 and a beta of 1.10.

Axcelis Technologies (NASDAQ:ACLS) last announced its quarterly earnings data on Thursday, August 3rd. The semiconductor company reported $0.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.01). The company had revenue of $102.80 million for the quarter, compared to the consensus estimate of $100.07 million. Axcelis Technologies had a net margin of 10.80% and a return on equity of 17.04%. The company’s revenue was up 59.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. equities analysts predict that Axcelis Technologies, Inc. will post 1.27 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Axcelis Technologies, Inc. (ACLS) Stake Maintained by Nationwide Fund Advisors” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/04/axcelis-technologies-inc-acls-stake-maintained-by-nationwide-fund-advisors.html.

In related news, CFO Kevin J. Brewer sold 17,339 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $20.75, for a total transaction of $359,784.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP William J. Bintz sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $22.57, for a total value of $282,125.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 106,641 shares of company stock valued at $2,347,514. 5.66% of the stock is currently owned by corporate insiders.

Several research firms have recently commented on ACLS. Craig Hallum lowered shares of Axcelis Technologies from a “buy” rating to a “hold” rating in a research report on Friday. B. Riley upped their price target on shares of Axcelis Technologies from $30.00 to $39.00 and gave the company a “buy” rating in a research report on Friday. Zacks Investment Research raised shares of Axcelis Technologies from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Thursday. Stifel Nicolaus upped their price target on shares of Axcelis Technologies from $20.00 to $31.00 and gave the company a “hold” rating in a research report on Wednesday. Finally, ValuEngine lowered shares of Axcelis Technologies from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. Axcelis Technologies has a consensus rating of “Hold” and an average price target of $31.33.

Axcelis Technologies Company Profile

Axcelis Technologies, Inc designs, manufactures and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. The Company also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services and customer training.

Institutional Ownership by Quarter for Axcelis Technologies (NASDAQ:ACLS)

What are top analysts saying about Axcelis Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axcelis Technologies Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit